105 results
8-K
EX-99.1
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
in the conference call, please register in advance here. To access the live and archived webcast, please visit Immunovant’s website at https
S-3ASR
EX-1.2
IMVT
Immunovant Inc
9 Nov 23
Automatic shelf registration
8:49am
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability … and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except in the case
424B5
IMVT
Immunovant Inc
29 Sep 23
Prospectus supplement for primary offering
4:48pm
will be available for review at the SEC’s website at www.sec.gov. We also maintain a website at www.immunovant.com, at which you may access these materials free
8-K
EX-1.1
ruawml xts
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
8-K
EX-10.1
erscj0d4 kojf8
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
424B5
1ls9bday6op
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
4ufve3 kj
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
424B5
qfbnn7kagr8z6gy ue
5 Oct 22
Prospectus supplement for primary offering
4:43pm
8-K
EX-1.1
gty gvjvwraz
4 Oct 22
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
5:28pm
8-K
EX-99.2
vce54f5
7 Sep 22
Regulation FD Disclosure
6:39am
8-K
EX-99.1
cyj2b3t 7ke5kq8il2w7
5 Aug 22
Results of Operations and Financial Condition
7:07am